<?xml version="1.0" encoding="UTF-8"?>
<p>Inoculation with IIVs is generally safe in adults.
 <xref rid="agm212102-bib-0027" ref-type="ref">
  <sup>27</sup>
 </xref>, 
 <xref rid="agm212102-bib-0028" ref-type="ref">
  <sup>28</sup>
 </xref>, 
 <xref rid="agm212102-bib-0029" ref-type="ref">
  <sup>29</sup>
 </xref>, 
 <xref rid="agm212102-bib-0030" ref-type="ref">
  <sup>30</sup>
 </xref> The most common adverse events are transient local reactions at the injection sites, such as pain, erythema, and swelling.
 <xref rid="agm212102-bib-0013" ref-type="ref">
  <sup>13</sup>
 </xref> Vaccination recipients without a history of influenza vaccine antigen exposure may experience transient symptoms, such as fever, malaise, and myalgia,
 <xref rid="agm212102-bib-0031" ref-type="ref">
  <sup>31</sup>
 </xref> but these do not occur frequently in adults.
 <xref rid="agm212102-bib-0032" ref-type="ref">
  <sup>32</sup>
 </xref> Those who have experienced severe anaphylaxis after influenza vaccination should not seek revaccination. It has been reported that TIV recipients are more likely to develop Guillain‐Barré syndrome,
 <xref rid="agm212102-bib-0033" ref-type="ref">
  <sup>33</sup>
 </xref>, 
 <xref rid="agm212102-bib-0034" ref-type="ref">
  <sup>34</sup>
 </xref> but no direct relationships between influenza vaccination and the syndrome have been reported.
 <xref rid="agm212102-bib-0035" ref-type="ref">
  <sup>35</sup>
 </xref> According to the monitoring data collated by the US vaccine adverse‐event reporting system, the total adverse reaction rate after TIV inoculation in recipients aged ≥ 65 years was approximately 16.5 per million doses from 1990 to 2005.
 <xref rid="agm212102-bib-0036" ref-type="ref">
  <sup>36</sup>
 </xref>
</p>
